Compare FIRY & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIRY | HUMA |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.8M | 165.7M |
| IPO Year | 2020 | 2020 |
| Metric | FIRY | HUMA |
|---|---|---|
| Price | $11.60 | $0.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.63 |
| AVG Volume (30 Days) | 129.6K | ★ 5.8M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,496,000.00 | $2,038,000.00 |
| Revenue This Year | $22.11 | $72.32 |
| Revenue Next Year | $7.99 | $518.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.52 | N/A |
| 52 Week Low | $7.92 | $0.34 |
| 52 Week High | $14.12 | $1.78 |
| Indicator | FIRY | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 36.62 |
| Support Level | $9.31 | $0.34 |
| Resistance Level | $14.02 | $0.75 |
| Average True Range (ATR) | 0.68 | 0.04 |
| MACD | -0.16 | 0.00 |
| Stochastic Oscillator | 49.35 | 39.45 |
Firy Inc, formerly Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. Its reportable segments are: the Skillz segment and the RZR segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is a performance marketing platform that enables advertisers to acquire, retain, and monetize users across mobile, connected television (CTV), and other digital channels. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube, among others. It generates the majority of its revenue from the Skillz segment. Geographically, the company derives its key revenue from the United States.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.